Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Fluoxetine
|
| gptkbp:activities |
dopamine receptor antagonist
|
| gptkbp:approves |
gptkb:1959
gptkb:FDA |
| gptkbp:brand |
Mellaril
|
| gptkbp:class |
thiazine derivative
|
| gptkbp:clinical_trial |
studies on efficacy
studies on safety studies on long-term effects studies on withdrawal effects |
| gptkbp:contraindication |
cardiac arrhythmias
hypersensitivity to thioridazine |
| gptkbp:current_use |
schizophrenia
psychotic disorders |
| gptkbp:developed_by |
Smith, Kline & French
|
| gptkbp:dosage_form |
gptkb:tablet
50 to 100 mg daily |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
thioridazine
|
| gptkbp:ingredients |
C20 H24 N2 S
|
| gptkbp:interacts_with |
gptkb:beer
CNS depressants antihypertensives |
| gptkbp:is_available_in |
gptkb:various_countries
|
| gptkbp:is_available_on |
oral tablet
|
| gptkbp:is_used_for |
treatment of schizophrenia
|
| gptkbp:lifespan |
15 to 30 hours
|
| gptkbp:market |
gptkb:2005
discontinued |
| gptkbp:metabolism |
liver
|
| gptkbp:products |
chlorpromazine
fluphenazine perphenazine thioridazine hydrochloride trifluoperazine |
| gptkbp:related_to |
phenothiazine
|
| gptkbp:side_effect |
seizures
drowsiness constipation dry mouth weight gain blurred vision neuroleptic malignant syndrome tardive dyskinesia agranulocytosis |
| gptkbp:status |
historical use
|
| gptkbp:type_of |
50-53-3
|
| gptkbp:wildlife |
monitor for signs of infection
avoid in elderly patients monitor ECG |